Search Results

• A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma

  A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine Versus Selumetinib (NSC# 748727) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) Not Associated With BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1)

• Beat Childhood Cancer Specimen Banking and Data Registry

  Specimen Banking With Clinical and Genomic Data Registry With the Establishment of Tumor Models for Pediatric Cancers

• Mechanical Properties and Esophageal Fibrosis in Eosinophilic Esophagitis

  Mechanical Properties and Esophageal Fibrosis in Eosinophilic Esophagitis

• EFFICACY AND COMPARISON OF TWO COMMONLY USED DOSES OF BETHANECHOL IN THE MANAGEMENT OF INFANT GASTROESOPHAGEAL REFLUX IN NEONATAL INTENSIVE CARE UNIT

  EFFICACY AND COMPARISON OF TWO COMMONLY USED DOSES OF BETHANECHOL IN THE MANAGEMENT OF INFANT GASTROESOPHAGEAL REFLUX IN NEONATAL INTENSIVE CARE UNIT

• DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma

  Phase II Trial of Eflornithine/DFMO as Maintenance Therapy for Molecular High Risk/Very High Risk and Relapsed/Refractory Medulloblastoma

• A Study to Evaluate Etrasimod Treatment in Adolescents With Ulcerative Colitis

  An Open-Label, Single-Arm Study to Evaluate the Efficacy, Pharmacokinetics, and Safety of Etrasimod in Adolescent Subjects with Moderately to Severely Active Ulcerative Colitis

• A U.S. Registry Of Eosinophilic Esophagitis Patients Treated With Dupixent As Standard Of Care

  A U.S. Registry Of Eosinophilic Esophagitis Patients Treated With Dupixent As Standard Of Care

• Phase 2 Study of Tovorafenib (DAY101) in Relapsed and Refractory Langerhans Cell Histiocytosis

  Phase 2 Study of Tovorafenib (DAY101) in Relapsed and Refractory Langerhans Cell Histiocytosis

• SkyPASS: A Prospective, Non-interventional (NIS), Long-term, Post-Authorisation Safety Study (PASS) of Patients Treated with Lonapegsomatropin

  SkyPASS: A Prospective, Non-interventional (NIS), Long-term, Post-Authorisation Safety Study (PASS) of Patients Treated with Lonapegsomatropin

• Open-Label Induction, Randomized Double-Blind Maintenance, and Long-Term Extension Periods in Pediatric Subjects (2 to < 18 Years of Age) with Moderately to Severely Active Crohn's Disease

  A Phase 3, Multi-Center Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Risankizumab with Open-Label Induction, Randomized